Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net income	$ 324,232	$ 223,281
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion	47,339	45,028
Impairment of long-lived assets	0	138,050
Amortization of debt related costs	3,217	3,227
Changes in fair value of contingent assets and liabilities	(1,405)	(9,475)
Inventory adjustments	738	5,251
Stock-based compensation	54,229	36,335
Gain on disposal of assets	(6,254)	(51,789)
Unrealized gain on investment in equity securities	(75,492)	0
Charges incurred in connection with acquired IPR&D	66,000	0
Deferred taxes	(4,402)	(57,649)
Long-term indemnification receivable	0	3,929
Long-term income tax payable and other long-term liabilities	2,619	(2,744)
Other	7,172	3,118
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	(44,887)	(43,044)
Inventory	(7,101)	(25,995)
Other current assets	1,335	2,496
Accounts payable	1,151	12,150
Accrued expenses and other liabilities	18,529	(89,196)
Net cash provided by operating activities	387,020	192,973
Cash flows from investing activities:
Capital expenditures	(35,256)	(34,486)
Acquisition of assets, net	(80,911)	(45,345)
Proceeds from sale of assets	8,000	97,839
Purchases of investment in equity securities	(83,246)	0
Acquisition of exclusive license option	(28,000)	0
Net cash (used in) provided by investing activities	(219,413)	18,008
Cash flows from financing activities:
Payments on long-term debt and other borrowings	(376)	(685)
Contingent value rights settlement	0	(3,700)
Proceeds from stock option exercises	3,772	3,462
Proceeds from issuance of common stock	3,450	1,933
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(21,723)	(13,621)
Net cash used in financing activities	(14,877)	(12,612)
Effect of foreign exchange rates on cash, cash equivalents and restricted cash	34	139
Net increase in cash, cash equivalents and restricted cash	152,764	198,508
Cash, cash equivalents and restricted cash, beginning of period	715,285	417,241
Cash, cash equivalents and restricted cash, end of period	868,049	615,749
Reconciliation to amounts within the condensed consolidated balance sheets
Cash and cash equivalents	866,386	614,131
Restricted cash included in other long-term assets	1,663	1,618
Cash, cash equivalents and restricted cash at end of period	868,049	615,749
Schedule of non-cash investing and financing activities
Additions of property, plant and equipment included in liabilities	8,502	8,573
Lease liability settled through transfer of lease	762	0
Right-of-use asset obtained in exchange for operating lease liabilities	$ 63	$ 29,625